Effect of different calcineurin inhibitors on AOPP and TAS after kidney transplantation.
OBJECTIVE
Little is known about the influence of calcineurin inhibitors on advanced oxidation protein products (AOPP) and total antioxidant status (TAS) after renal transplantation.


METHODS
AOPP and TAS were evaluated in transplanted patients on different calcineurin inhibitors. Thirty-five patients were treated with cyclosporine A (group A) and 33 with tacrolimus (group B).


RESULTS
Over 6 months, the mean levels of AOPP in group A decreased from 205.9+/-125.7 to 140.9+/-78.9 micromol/L and TAS from 1.89+/-0.30 to 1.75+/-0.27 mmol/L. In group B, the mean levels of AOPP decreased from 196.5+/-123.9 to 129.6+/-63.8 micromol/L and TAS from 1.80+/-0.39 to 1.78+/-0.23 mmol/L.


CONCLUSIONS
No significant differences in AOPP and TAS were found with respect to treatment. The only exception was the higher mean concentration of AOPP at month 1 in group A (p=0.026).
Zadrazil
Josef
J
Department of Internal Medicine III, University Hospital, I. P. Pavlova 6, 775 20 Olomouc, Czech Republic. josef.zadrazil@fnol.cz
Strebl
Pavel
P
Krejcí
Karel
K
Horcicka
Vladko
V
Horák
Pavel
P
Vostálová
Jitka
J
Zdarilová
Adéla
A
Kajabová
Markéta
M
Schneiderka
Petr
P
D000328:Adult; D000368:Aged; D000975:Antioxidants / Q000378:metabolism*; D065095:Calcineurin Inhibitors; D016572:Cyclosporine / Q000494:pharmacology; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007676:Kidney Failure, Chronic / Q000378:metabolism / Q000534:rehabilitation / Q000628:therapy; D016030:Kidney Transplantation / Q000534:rehabilitation; D008297:Male; D008875:Middle Aged; D018384:Oxidative Stress / Q000187:drug effects*; D011506:Proteins / Q000378:metabolism*; D016559:Tacrolimus / Q000494:pharmacology
D000975:Antioxidants; D065095:Calcineurin Inhibitors; D004791:Enzyme Inhibitors; D011506:Proteins; D016572:Cyclosporine; D016559:Tacrolimus